Slide 1: Cell Biotech – Probiotics & Microbiome company
CELL BIOTECH Probiotics & Microbiome company 1
Slide 2: Revenue up 1.2% to KRW 25.6 billion, operating profit KRW 3.6 billion
CELL BIOTECH Revenue up 1.2% to KRW 25.6 billion, operating profit KRW 3.6 billion Domestic revenue down 15.1%, overseas revenue up 23.1% Duolac brand sales dawn 14.2% to KRW 12.6 billion, OEM/ODM sales up 24.1% to KRW 10.0 billion, Raw material sales up 18.2% to KRW 3 billion (unit : KRW 100 mil) 2
Slide 3: 1H revenue KRW 25.6 billion, yoy +1.2%
CELL BIOTECH 1H revenue KRW 25.6 billion, yoy +1.2% Quarterly revenue Full year revenue (unit: KRW mil) (unit : KRW mil) 53,787 50,526 46,873 3
Slide 4: 1H operating profit KRW 3.6 billion
CELL BIOTECH 1H operating profit KRW 3.6 billion, Quarterly profit Full year profit (unit: KRW mil) (unit: KRW mil) 4
Slide 5: 2Q revenue of Duolac brand, OEM/ODM and raw material
CELL BIOTECH 2q revenue of Duolac brand -8.7% to 6.0 KRW bil., OEM/ODM -9.0% to 4.8 KRW bil., and raw material +46.4% to 1.8 KRW bil. (unit : KRW mil) 15,000 13,000 11,000 9,000 7,000 5,000 3,000 '21.3Q '21.4Q '22.1Q '22.2Q '22.3Q '22.4Q 23.1Q 23.2Q 23.3Q 23.4Q 24.1Q2 24.2Q Duolac-domestic Duolac-ov
Slide 6: Microbiome R&D
CELL BIOTECH Microbiome R&D No. 1 in global export for 11 consecutive years 1) Microbiome First-in-Class anticancer pipeline ‘PP-P8’ 1) Cell Biotech "Duolac, No. 1 in domestic probiotic exports for 11 clinical phase 1 IND submitted (Mar 5, 2021) consecutive years. 2) Acquisition European patent of P
Slide 7: Income statement and statement of financial position
CELL BIOTECH Income statement (unit : KRW 100 mil., %) Statement of financial position (unit : KRW 100 mil., %) 7